TFF Pharmaceuticals provided an update from the Company’s ongoing Phase 2 trial of Tacrolimus Inhalation Powder, TFF TAC, for the prevention of lung transplant rejection. “The growing body of data from the TFF TAC Phase 2 study continues to suggest that TFF TAC has transformative potential to advance the field of immunosuppressive therapy to prevent lung transplant rejection,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals. “We are finalizing the design of the next study with TFF TAC in close collaboration with our clinical investigators and in communication with regulatory authorities and look forward to providing additional updates on the program including a regulatory update later in the fall.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFFP:
- TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
- One new option listing and eighteen option delistings on July 22nd
- TFF Pharmaceuticals engages Outcome Capital as strategic advisor
- TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
- TFF Pharmaceuticals submits briefing book to the FDA for TFF TAC development